文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤后国际标准化比值与活化部分凝血活酶时间的变异性不能由凝血因子缺乏解释

Variability in international normalized ratio and activated partial thromboplastin time after injury are not explained by coagulation factor deficits.
PubMed 文献 · J Trauma Acute Care Surg · 2019-01-01
一句话结论严重创伤患者中,凝血因子活性无法解释近半数PT/INR与aPTT变异,延长的PT/INR和aPTT对内源或外源通路因子缺乏预测价值差,但可提示共同通路缺乏。

该前瞻性数据库研究纳入60例既往无凝血因子缺乏的严重创伤患者,于急诊科到达时检测凝血因子活性、PT/INR、aPTT和纤维蛋白原。线性回归显示凝血因子活性仅能解释44.6%的PT/INR变异和49.5%的aPTT变异。凝血因子缺乏率:共同通路25%、外源通路1.7%、内源通路6.7%。PT/INR大于1.3对外源通路缺乏的阳性预测值为4.4%、对共同通路缺乏为56.5%;aPTT大于34秒对内源通路缺乏的阳性预测值为16.7%、对共同通路缺乏为73.7%。

要点

  • 严重创伤患者中,凝血因子活性仅能解释44.6%的PT/INR变异和49.5%的aPTT变异,近半数变异原因未明。
  • PT/INR大于1.3对外源通路凝血因子缺乏的阳性预测值仅4.4%,对共同通路缺乏为56.5%。
  • aPTT大于34秒对内源通路凝血因子缺乏的阳性预测值仅16.7%,对共同通路缺乏为73.7%。
  • 凝血因子缺乏率:共同通路25%、外源通路1.7%、内源通路6.7%(缺乏定义为活性小于30%,纤维蛋白原小于150 mg/dL)。
  • 延长的PT/INR和aPTT是内源或外源通路因子缺乏的差预测指标,但可提示共同通路因子缺乏。

适用人群与场景

  • 既往无凝血因子缺乏的严重创伤患者,于急诊科到达时检测,来自ACS认证的Level I创伤中心前瞻性数据库,2014年至2017年。
  • 排除既往凝血因子缺乏者;纳入患者平均年龄35.8岁(SD 13.6),新损伤严重度评分中位数32(四分位距12-43),53.3%为钝性伤,23.3%需大量输血,死亡率11.67%。

诊断标准与关键阈值

  • PT/INR延长定义为INR大于1.3;aPTT延长定义为大于34秒。
  • 凝血因子缺乏定义为活性小于30%,纤维蛋白原缺乏定义为小于150 mg/dL。

研究设计与关键结果

  • 研究类型为前瞻性数据库研究,样本量60例,单中心(ACS认证的Level I创伤中心),人群为既往无凝血因子缺乏的严重创伤患者。
  • 主要终点:线性回归显示凝血因子活性仅能解释44.6%的PT/INR变异和49.5%的aPTT变异,其余变异未解释。
  • 凝血因子缺乏率:共同通路25%、外源通路1.7%、内源通路6.7%。
  • PT/INR大于1.3对外源通路凝血因子缺乏的阳性预测值为4.4%,对共同通路缺乏为56.5%。
  • aPTT大于34秒对内源通路凝血因子缺乏的阳性预测值为16.7%,对共同通路缺乏为73.7%。

证据类型、等级与局限

  • 证据类型:前瞻性数据库研究,预后性证据,证据等级Level III(原文标注)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在严重创伤患者中,延长的PT/INR和aPTT不应被视为内源或外源通路凝血因子缺乏的可靠指标,因其阳性预测值分别仅为4.4%和16.7%。
  • 延长的PT/INR和aPTT可提示共同通路凝血因子缺乏,阳性预测值分别为56.5%和73.7%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Conventional coagulation assays (CCAs), prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT), detect clotting factor (CF) deficiencies in hematologic disorders. However, there is controversy about how these CCAs should be used to diagnose, treat, and monitor trauma-induced coagulopathy. Study objectives were to determine whether CCA abnormalities are reflective of deficiencies of coagulation factor activity in the setting of severe injury.

METHODS: Patients without previous CF deficiency within a prospective database at an ACS-verified Level I trauma center had CF activity levels, PT/INR, aPTT, and fibrinogen levels measured upon emergency department arrival from 2014 to 2017. Linear regression assessed how CF activity explained the aPTT and PT/INR variation. Prolonged CCA values were set as INR greater than 1.3 and aPTT greater than 34 seconds. CF deficiency was defined as less than 30% activity, except for fibrinogen, defined as less than 150 mg/dL.

RESULTS: Sixty patients with a mean age of 35.8 (SD, 13.6) years and median New Injury Severity Score of 32 (interquartile range, 12-43) were included; 53.3% sustained blunt injuries, 23.3% required massive transfusion, and mortality was 11.67%. Overall, 44.6% of the PT/INR variance and 49.5% of the aPTT variance remained unexplained by CF activity. Deficiencies of CFs were: common pathway, 25%; extrinsic pathway, 1.7%; and intrinsic pathway, 6.7%. The positive predictive value for CF deficiencies were: (1) PT/INR greater than 1.3:4.4% for extrinsic pathway, 56.5% for the common pathway; (2) aPTT greater than 34 seconds:16.7% for the intrinsic pathway, 73.7% for the common pathway.

CONCLUSION: Almost half of the variances of PT/INR and aPTT were unexplained by CF activity. Prolonged PT/INR and aPTT were poor predictors of deficiencies in the intrinsic or extrinsic pathways; however, they were indicators of common pathway deficiencies.

LEVEL OF EVIDENCE: Prognostic, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Stettler GR, Moore EE, Moore HB, et al. Variability in international normalized ratio and activated partial thromboplastin time after injury are not explained by coagulation factor deficits. J Trauma Acute Care Surg. 2019. PMID: 31136528. doi:10.1097/TA.0000000000002385

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。